# PEER-REVIEW-PACKAGE-RP-002 — Enterprise DNA

**Research ID:** NRI-RP-002-PEER  
**Program:** RP-002 Enterprise DNA  
**Version:** 1.2  
**Status:** Pass — WP Draft Allowed  
**Objective:** Package review scope, checklist, and decision outcomes so a non-author reviewer can pass/hold RP-002 toward White Paper draft — without self-certification  
**Scope:** In: review package / Out: Approval by author; Constitution/Blueprint/Kernel/Runtime edits; Eng ingest; DNA as authorization input  
**Author:** NRI  
**Reviewer:** **臻宇**（非作者；亦为 RP-001 peer）  
**Approval:** Pass — WP Draft Allowed（peer decision recorded）  
**Dependencies:** EDNA, Evidence Pack, Deliverables, SC-01…03, Industry Analysis, Risk Analysis  
**Promotion Status:** Research Library  
**Classification:** Research Only — Not Normative for Implementation  
**Last Updated:** 2026-07-21  
**Assignment record:** `RP-002 peer = 臻宇`（2026-07-21）  
**Decision record:** PR-DNA-01…12 all **Yes / Pass**; outcome **Pass → WP Draft Allowed**（2026-07-21）  
**Governing Directive:** [RESEARCH_GOVERNANCE_CHARTER.md](../../RESEARCH_GOVERNANCE_CHARTER.md)

---

## 1. Why This Package Exists

NRI-VAL: *No self-certification for White Paper or later stages.*  
Chief Architect / author **must not** set `Reviewer` to self or mark White Paper Approved.

EDNA’s critical invariant: DNA is a **constraint vector**, never an authorization input and never grants Permission.

## 2. Review Corpus (read in order)

| # | Artifact | Path | Role |
|---|----------|------|------|
| 1 | Program Brief | [README.md](README.md) | 21 dimensions |
| 2 | EDNA | [ENTERPRISE_DNA_MODEL.md](ENTERPRISE_DNA_MODEL.md) | DX-01…08 core model |
| 3 | Evidence Pack | [EVIDENCE_PACK.md](EVIDENCE_PACK.md) | Claims + WP gate |
| 4 | Deliverables | [DELIVERABLES-RP-002.md](DELIVERABLES-RP-002.md) | Charter 16 |
| 5 | Industry Analysis | [INDUSTRY_ANALYSIS.md](INDUSTRY_ANALYSIS.md) | P-DNA-01…10 |
| 6 | Risk Analysis | [RISK_ANALYSIS.md](RISK_ANALYSIS.md) | R-DNA-01…14 |
| 7 | SC-01 | [scorecards/SC-01-wt01-mfg.md](scorecards/SC-01-wt01-mfg.md) | MFG DNA profile |
| 8 | SC-02 | [scorecards/SC-02-wt02-svc.md](scorecards/SC-02-wt02-svc.md) | Services DNA profile |
| 9 | SC-03 | [scorecards/SC-03-wt03-contrast.md](scorecards/SC-03-wt03-contrast.md) | Stage contrast |

Estimated desk review: **2–3 hours**.

## 3. Reviewer Checklist (pass/fail)

| ID | Check | Pass? | Notes |
|----|-------|-------|-------|
| PR-DNA-01 | Library metadata complete on all corpus items | **Yes / Pass** | |
| PR-DNA-02 | Hard boundaries intact (no Kernel/Runtime/Const/BP edits proposed as done) | **Yes / Pass** | |
| PR-DNA-03 | DX-01…08 teachable; no single composite “DNA IQ” claimed as truth | **Yes / Pass** | |
| PR-DNA-04 | V-DNA-01…05 construct coverage adequate for Research Draft | **Yes / Pass** | |
| PR-DNA-05 | Evidence tiers honestly labeled (synthetic = T1, not T3) | **Yes / Pass** | |
| PR-DNA-06 | Falsifiers present; instability / culture-quiz collapse covered | **Yes / Pass** | |
| PR-DNA-07 | Non-authorization invariant explicit (`authorization_input: never`) | **Yes / Pass** | |
| PR-DNA-08 | Downstream RP-007 constraint hints consumable without auto-execution | **Yes / Pass** | |
| PR-DNA-09 | Industry patterns P-DNA-01…10 coherent with SC-01…03 | **Yes / Pass** | |
| PR-DNA-10 | Risk register covers discrimination / privacy / arch misuse | **Yes / Pass** | |
| PR-DNA-11 | Deliverables #1–3, #8–10, #12, #15 at least Draft | **Yes / Pass** | |
| PR-DNA-12 | No Eng soft-queue / Explicit Defer openings requested | **Yes / Pass** | |

## 4. Decision Outcomes (reviewer fills)

| Outcome | Meaning | Required Actions |
|---------|---------|------------------|
| **Pass → WP Draft Allowed** | Peer accepts Research Draft quality for White Paper drafting | Author may open WP template |
| **Hold** | Remediable gaps | List blockers below; stage stays Research |
| **Reject** | Material integrity failure | Cite PR-DNA-* failures; do not draft WP |

**Selected outcome:** **Pass → WP Draft Allowed**  
**Reviewer name:** **臻宇**  
**Date assigned:** 2026-07-21  
**Date decided:** 2026-07-21  
**Blockers (if Hold/Reject):** _none_

### Decision note

Peer Pass 已记录（PR-DNA-01…12）。White Paper **内容** Approval 仍独立（见 [WHITE_PAPER-RP-002.md](WHITE_PAPER-RP-002.md)）。Pass ≠ Architecture Review ≠ DNA→grant ≠ Eng ingest。

## 5. Explicit Non-Outcomes

Peer Pass does **not**:

- Approve White Paper content (separate WP review)  
- Promote to Blueprint / Constitution / Implementation  
- Open Twin authorize / Brain execute / DNA→grant  
- Satisfy live T3 enterprise evidence  
- Replace Organization Kernel attributes with DNA scores  

## Related Documents

- [NRI Validation Rules](../../RESEARCH_VALIDATION_RULES.md)  
- [Dual-Track Playbook](../../../project/DUAL_TRACK_GOVERNANCE.md)  
- [Wave 1 Peer Assignment](../../WAVE1_PEER_ASSIGNMENT.md)  
- [Wave 2 Peer Assignment](../../WAVE2_PEER_ASSIGNMENT.md)  
